Related Experiment Video
Updated: Apr 21, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Intravitreal bevacizumab treatment of retinal telangiectasis complicated by subretinal neovascularization
Mehmet Cakir1, Zerrin Bayraktar, Sukru Bayraktar
1From Beyoglu Eye Research and Education Hospital, Istanbul, Turkey.
Background:
Idiopathic perifoveal telangiectasia (IPT) is a disorder characterized by focal parafoveal capillary dilatation of unknown cause. Photodynamic therapy (PDT) was reported to be efficacious in the treatment of subretinal neovascularization (SRN) associated with idiopathic juxtafoveal retinal telangiectasis. However, visual improvement is limited.
Methods:
We describe the clinical, angiographic, and optical coherence tomography findings for a patient with IPT complicated with SRN and treated with PDT and bevacizumab.
Results:
The patient underwent 2 sessions of PDT; however, metamorphopsia persisted, and visual acuity further decreased to 20/100 after the second PDT. Two injections of intravitreal bevacizumab (1.25 mg) were administered after PDT. Visual acuity increased dramatically from 20/100 to 20/25 after the injections. Four months after the second injection, there was no recurrence, and the patient was asymptomatic.
Conclusion:
Intravitreal bevacizumab treatment should be considered for patients with SRN associated with perifoveal telangiectasis, especially after insufficient therapeutic response to PDT.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Diabetic Retinopathy

